Jennifer Daniel, APRN
Nurse Practitioner · Danville, KYNPI 1669875241
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.3% of the total across 364 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,895, 2.5 times the $764 reported in 2021. Among nurse practitioner clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 364 payments — averaging $19.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$1K
- Takeda Pharmaceuticals U.S.A., Inc.$759
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$694
- Harmony Biosciences LLC$602
- Regeneron Healthcare Solutions, Inc.$343
- Boehringer Ingelheim$286
- plus $3K from 33 others
What the payments were for
- Food & beverage$6,59994%
- Education$3976%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$6,996 in reported general payments places this provider in the 90th percentile of 1,918 nurse practitioner providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pregabalin | 11 | $1,979 |
| Armodafinil | 18 | $1,183 |
| Zolpidem Tartrate | 150 | $646 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 22 | $400 |
| Clonazepam | 52 | $398 |
| Hydroxyzine Hcl | 48 | $285 |
| Ropinirole Hcl | 18 | $256 |
| Quetiapine Fumarate | 27 | $208 |
| Gabapentin | 29 | $204 |
| Trazodone Hcl | 24 | $169 |
| Levocetirizine Dihydrochloride | 16 | $114 |
| Buspirone Hcl | 12 | $80 |
| Temazepam | 26 | $69 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Danville
- Rachael BradfordLexington$447K
- Tara MuddLouisville$243K
- Lee HaasLouisville$95K
- Ashley KnableLouisville$86K
- Christina BenningerLouisville$81K
- Courtney BowlingCampbellsville$47K
- Rebecca BraunerLouisville$40K
- Scott SeitzWinchester$34K
- Kristen KreinestEdgewood$34K
- Lillian ArgentEdgewood$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.